Projekt

Randomized phase II study to investigate the efficacy, safety and tolerability of ZK 230211 (25 mg vs. 100 mg) as second-line endocrine therapy for postmenopausal women with hormonereceptor-positive metastatic breast cancer

Abgeschlossen · 2008 bis 2009

Art
Klinische Forschung
Reichweite
Multizentrisch, KSSG als teilnehmendes Zentrum
Bereiche
Status
Abgeschlossen
Start
2008
Ende
2009
Finanzierungsart
Industrie
Studiendesign
Prospective, randomized, open-label, parallel group, multi-center
Schlagwörter (Tags)
hormone receptor-positive tumors, breast cancer
Projektpartner
Prof. Walter Jonat, Kiel, Klinik für Gynäkologie und Geburtshilfe Dr. Iris Kuss Bayer Schering Pharma AG, Study Team Lead, Dr. Michael, Bayer Schering Pharma AG, Dr. Kretschmann Bayer Schering Pharma AG
Kurzbeschreibung/Zielsetzung

Breast cancer is the second leading cause of cancer-related death in women today (after lung cancer) and is the most common cancer among women worldwide. According to the World Health Organization (WHO), more than 1.2 million people will be diagnosed with breast cancer worldwide in 2005 (Imaginis 2005).
The risk of developing breast cancer increases with age with about two thirds of breast cancers occurring in postmenopausal women. Endocrine therapy is the most important systemic treatment for patients with hormone receptor-positive tumors, which account for two thirds of
breast cancers.